Gossamer Bio Inc., a clinical biopharmaceutical company, has announced new compensation terms for three non-executive employees. The company's Compensation Committee has approved the grant of non-qualified stock option awards, allowing the purchase of up to 168,750 shares of Gossamer's common stock under their 2023 Employment Inducement Incentive Award Plan. Effective August 5th, 2025, these options are priced at $2.16 per share, matching the closing price on the Nasdaq Global Select Market on that date. The options have a ten-year term and will vest over four years, with an initial 25% vesting after one year and the rest vesting in monthly installments, contingent upon continued employment with the company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。